Genmab A/S (NASDAQ:GMAB) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp trimmed its position in Genmab A/S (NASDAQ:GMABFree Report) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,944 shares of the company’s stock after selling 2,028 shares during the period. Fifth Third Bancorp’s holdings in Genmab A/S were worth $1,590,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. First Manhattan Co. acquired a new stake in Genmab A/S in the fourth quarter valued at approximately $26,000. Headlands Technologies LLC acquired a new stake in shares of Genmab A/S during the third quarter worth $27,000. NBC Securities Inc. acquired a new stake in shares of Genmab A/S during the third quarter worth $37,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Genmab A/S by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after buying an additional 498 shares during the period. Finally, UMB Bank n.a. lifted its stake in shares of Genmab A/S by 234.4% during the third quarter. UMB Bank n.a. now owns 1,478 shares of the company’s stock worth $52,000 after buying an additional 1,036 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GMAB shares. Citigroup downgraded shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, March 27th. Truist Financial reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. UBS Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, December 6th. Finally, BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $48.50.

Read Our Latest Report on GMAB

Genmab A/S Stock Down 2.2 %

GMAB stock opened at $29.30 on Thursday. The stock has a market capitalization of $19.36 billion, a P/E ratio of 30.52, a P/E/G ratio of 1.41 and a beta of 0.99. The firm has a 50-day simple moving average of $29.03 and a 200-day simple moving average of $30.83. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.99.

Genmab A/S (NASDAQ:GMABGet Free Report) last released its earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to analysts’ expectations of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. On average, analysts expect that Genmab A/S will post 1.09 earnings per share for the current year.

Genmab A/S Profile

(Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Stories

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMABFree Report).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.